

December 22, 2023

Contents

Clinical Profile Documentation	2
Additions.....	2
Problems.....	2
Additions.....	2
Lab Analytes & Panels.....	2
Additions.....	2
Medications.....	3
Additions.....	3
Updates.....	3
Regimen Library.....	4
Additions.....	4
Updates.....	5
Renames.....	6
Research.....	6
Updates.....	6
Billing & HCPCS Codes	7
CMS-Hierarchical Condition Categories (HCC)	7
HCPCS Updates	7
NDC to HCPCS Crosswalk.....	10
Additions.....	10

Clinical Profile Documentation

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

AKT1 is now available for **Breast Cancer** with the following documentation points:

- Wild-type
- Mutation
- Unknown

PSMA is now available for **Prostate Cancer** with the following documentation points:

- Positive
- Negative
- Not performed

PTEN is now available for **Breast Cancer** with the following documentation points:

- Wild-type
- Mutation
- Unknown

Problems

Additions

New items are available for documentation in **Problems** and appear in the **Charge Capture Report (CCR)**. Additional ICD-10 codes* may be displayed to present the surrounding nodes.

Lab Analytes & Panels

Additions

- Beta HCG, U/L
- Dabigatran (Pradaxa) interpretation
- EBV DNA PCR, quant, log IU/mL
- GFR female
- GFR male
- Herpes virus 6 DNA PCR, quant, copies/mL
- Lyme Disease ab, IgG, blot

- Lyme Disease ab, IgM, blot
- Prealbumin, mg/L
- RBC antigen 1
- RBC antigen 2
- RBC antigen 3
- RBC antigen 4
- RBC antigen 5
- Respiratory culture

Medications

Additions

- BA3071 invest IV
- Chiauranib invest Oral
- CHM-1101 invest Intratumoral
- CHM-1101 invest Intraventricular
- ERAS-254 invest Oral
- FF-10832 invest IV
- Gemcitabine Liposome invest (FF-10832 invest IV)
- IDE161 invest Oral
- MT-8421 invest IV
- Naporafenib invest (ERAS-254 invest Oral)
- RNK05047 invest IV
- Sodium Citrate IV
- ZW25 invest or JZ598 invest IV
- Zanidatamab invest (ZW25 invest or JZP958 invest IV)

Updates

Medication	Update
Budigalimab invest (ABBV-181 invest IV)	Obsolete Form : 100 mg solution New Form available: 100 mg recon soln
Ferric Carboxymaltose IV	New default sig : 750 mg intravenously once; administer over 15 minutes; admixture fluid 250 ml of 0.9 % Sodium Chloride

Medication	Update
	New Maximum Single Dose : 1000 mg New Instructions available: May also give undiluted by slow IV Push at a rate of approximately 100 mg (2 mL) per minute or 15 minutes for 1,000 mg dose. Observe for signs and symptoms of hypersensitivity reactions for at least 30 minutes following the administration. For iron deficiency anemia, if weight less than 50 kg the recommended dose is 15 mg/kg.
Fruzaqla (fruquintinib Oral)	New Maximum Single Dose : 5 mg
Fruzaqla invest (HMPL-013 invest Oral) Nirogacestat invest Oral	No longer available to order
Oxycodone Oral Liquid	Inactive default sig : 5 mL orally every 4 to 6 hours prn pain; quantity sufficient for 12 days New default sig available: 5 mL orally every 4 to 6 hours prn pain; quantity sufficient for 10 days
TJ033721 invest IV	New Form available: 200 mg/4 mL (50 mg/mL) solution
TTX-030 invest IV	New Form available: 30 mg/mL solution

Regimen Library

Nyvepria™ Precheck in Long-Acting G-CSF-containing Regimens

After reviewing utilization trends, economics, and commercial coverage, the P&T Executive Committee voted to precheck Nyvepria™ (pegfilgrastim-apgf) in all regimens containing long-acting G-CSFs. All regimens have been updated with the December content release.

Additions

Regimen Name	Diagnosis
Amivantamab-vmjw (weight less than 80 kg) + Pemetrexed + Carboplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Amivantamab-vmjw (weight less than 80 kg) + Pemetrexed Q21D Maintenance	Lung Cancer, Non-small Cell (NSCLC)
Amivantamab-vmjw (weight greater than or equal to 80 kg) + Pemetrexed + Carboplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)

Regimen Name	Diagnosis
Amivantamab-vmjw (weight greater than or equal to 80 kg) + Pemetrexed Q21D Maintenance	Lung Cancer, Non-small Cell (NSCLC)
Capivasertib + Fulvestrant Q28D	Breast Cancer
Fruquintinib Q28D	Colon Cancer; Rectal Cancer
Mirikizumab-mrkz IV (Induction) fb SQ (Maintenance) Q28D	Ulcerative Colitis
Nirogacestat Q30D	Desmoid Fibromatosis
Repotrectinib Q30D	Lung Cancer, Non-small Cell (NSCLC)
Rituximab IV D1,15 + Vemurafenib Q28D (Part 2 of 2: Rituximab Consolidation)	Leukemia, Hairy Cell
Rituximab IV D1,15,29,43 + Vemurafenib D1-56 (Part 1 of 2: Induction)	Leukemia, Hairy Cell
Toripalimab-tpzi (Flat Dose) + Gemcitabine D1,8 + Cisplatin Q21D (Part 1 of 2)	Head and Neck Cancer (Parent)
Toripalimab-tpzi Q21D (Flat Dose) (Part 2 of 2: Maintenance)	Head and Neck Cancer (Parent)
Toripalimab-tpzi (3 mg/kg) Q14D	Head and Neck Cancer (Parent)

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include reference updates, drug infusion instruction updates, renaming regimens, premedication template updates and number of cycles.

- Anal Cancer (Parent)
- Brain Tumor (Parent)
- Breast Cancer
- Colon Cancer
- Leukemia, Acute Lymphocytic (ALL)
- Leukemia, Acute Myeloid (AML)
- Leukemia, Acute Promyelocytic (APL)
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Bile Duct Cancer (Parent)
- Colon Cancer
- Esophageal Cancer (Parent)
- Gallbladder Cancer
- Gastric Cancer
- Neuroendocrine Tumor, Carcinoid (Parent)

- Pancreatic Cancer
- Pancreatic Cancer, Carcinoid/Neuroendocrine
- Rectal Cancer
- Waldenstrom's Macroglobulinemia

Renames

Previous Name	New Name
Intrathecal Chemotherapy	Intrathecal Therapy

Research

Updates

	Updated Reference Information			
		Updated Drug Service Order Information		
			Updated Regimen Instructions	
			Other Changes	
USOR 19043	X	X		
USOR 20138	X	X	X	Now available: USOR 20138 Continued Access Phase Capivasertib + Abiraterone + Prednisone
USOR 20270			X	
USOR 21318	X			No longer available: USOR 21318 Entrectinib (PO; Daily) Q28D USOR 21318 Pralsetinib (PO; Daily) Q28D
USOR 21537		X		
USOR 21541	X	X	X	
USOR 22041	X	X	X	
USOR 22052		X		
USOR 22073	X	X		
USOR 22088	X	X	X	
USOR 22159	X	X		
USOR 22167		X		
USOR 22187	X	X	X	

	Updated Reference Information			
	Updated Drug Service Order Information			
	Updated Regimen Instructions			
	Other Changes			
USOR 22229	X	X	X	
USOR 22331	X	X	X	
USOR 23016	X			
USOR 23027		X		
USOR 23087	X	X	X	
USOR 23172	X	X	X	Now available: USOR 23172 Cohort B Induction Phase Futibatinib (PO; Daily) + Pembrolizumab + mFOLFIRINOX Q14D

Billing & HCPCS Codes

2024 AMA CPT Updates

The 2024 CPT updates include:

- Added: 230
- Deleted: 49
- Revised: 70

CMS-Hierarchical Condition Categories (HCC)

The CMS HCC model is now on Version 28; For a complete list of ICD-10-CM codes please visit CMS [Risk Adjustment](#) 2024 Model Software/ICD-10 Mappings.

HCPCS Updates

The January 2024 updates include new HCPCS Level II codes to separately identify products approved under the 505(b)(2) New Drug Application (NDA) or the Biologics License Applications (BLA) pathways after October 2003, and *not rated as therapeutically equivalent* to a reference listed product in an existing code. A complete application summary and coding link can be found [here](#).

For a complete list of **January 2024 [HCPCS quarterly updates](#)**, please visit CMS's website.

The following products have **not been released** into the marketplace:

- Docetaxel (Ingenus)
- Daxibotulinumtoxina-lanm
- Methotrexate (Accord)
- Paclitaxel protein-bound particles (Teva)
- Pemetrexed (Pemrydi rtu)

Medication	HCPCS Codes
Adalimumab-afzb (Abrilada)	Q5132 per 10 mg
Amisulpride	J0184 per 1 mg
Aripiprazole (Abilify Asimtufii)	J0402 per 1 mg
Artesunate	J0391 per 1 mg
beremagene geperpavec-svdt Topical Gel 5 x 10exp9 PFU/2.5 mL	J3401 per 0.1 mL
Bumetanide	J1939 per 0.5 mg
Bortezomib (Maia) <i>*Effective 10/1/23</i>	J9051 per 0.1 mg
Buprenorphine Subcutaneous ER Solution	J0576 per 1 mg
Carmustine (Accord), not therapeutically equivalent to j9050	J9052 per 100 mg
Cefazolin sodium (Hikma), not therapeutically equivalent to j0690	J0688 per 500 mg
Cyclophosphamide (Dr. Reddy's)	J9072 per 5 mg
Daptomycin (Xellia) not therapeutically equivalent to j0878	J0873 per 1 mg
Delandistrogene Moxeparvc-rokl	J1413 per 1 mL
Dexmedetomidine Buccal Film Dexmedetomidine Sublingual Film	J1105 per 1 mcg
Efgartigimod-hyaluronidase-qvfc Subcutaneous 1,008 mg-11,200 unit/5.6 mL	J9334 per 2 mg
Emtricitabine-Tenofovir Oral 200 mg-25 mg	J0751 per 1 tab
Emtricitabine-Tenofovir Oral 200 mg-300 mg	J0750 per 1 tab
Epcoritamab-bysp Subcutaneous	J9321 per 0.16 mg
Fludeoxyglucose F-18	A9609 per 15 mci
Fluoroestradiol F-18 IV 148 MBq/mL to 3,700 MBq/mL	A9608 per 1 mci
Fluphenazine IM	J2679 per 1.25 mg

Medication	HCPCS Codes
Hydroxocobalamin IM	J3425 per 10 mcg
Glofitamab-gxbm	J9286 per 2.5 mg
Glycopyrrolate	J1596 per 0.1 mg
Nicardipine IV	J2404 per 0.1 mg
Pegunigalsidase alfa-iwxj	J2508 per 1 mg
Risperidone (Uzedy)	J2799 per 1 mg
Rozanolixizumab-noli	J9333 per 1 mg
Secukinumab Subcutaneous	J3590 per 150 mg
Sincalide (maia)	J2806 per 5 mcg
Talquetamab-tgvs	J3590 per: <ul style="list-style-type: none"> • 3 mg • 40 mg
Tirzepatide (weight loss) Subcutaneous Pen	J3490 per 5 mg
Tofersen Intrathecal	J1304 per 1 mg
Toripalimab-tpzi (Loqtorzi)	J9999 per 240 mg
Valoctocogene roxaparvovc-rvox IV (Roctavian)	J1412 per 1 mL
Velmanase alfa-tycv	J0217 per 1 mg

NDC to HCPCS Crosswalk

Additions

Medication (Brand)	HCPCS Code	NDC
Aripiprazole (Abilify Asimtufii)	J0402	<ul style="list-style-type: none"> • 59148010280 • 59148011480
Carmustine (Accord)	J9052	<ul style="list-style-type: none"> • 16729054863 • 16729054305 • 16729054601 • 16729054563
Cefazolin sodium (Hikma)	J0688	<ul style="list-style-type: none"> • 00143914025 • 00143914001 • 00143913925 • 00143913901
Cyclophosphamide (Dr. Reddy's)	J9072	<ul style="list-style-type: none"> • 43598066211 • 43598066011 • 43598066111
Daptomycin (Xellia)	J0873	<ul style="list-style-type: none"> • 70594005301
Sincalide (maia)	J2806	<ul style="list-style-type: none"> • 72266024801 • 72266024805